DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: TREATMENTS
       *****************************************************
       #Post#: 3466--------------------------------------------------
       COVID-19 in patients w/MS undergoing disease-modifying treatment
       s
       By: agate Date: November 17, 2021, 1:19 am
       ---------------------------------------------------------
       From Multiple Sclerosis Journal (December 2021)--"COVID-19 in
       patients with multiple sclerosis undergoing disease-modifying
       treatments":
  HTML https://journals.sagepub.com/doi/full/10.1177/1352458520971817
       #Post#: 3619--------------------------------------------------
       (AAN) COVID-19 rates high among vaccinated MS patients on some D
       MTs
       By: agate Date: April 20, 2022, 1:40 am
       ---------------------------------------------------------
       In the New England Journal of Medicine Journal Watch (April 15,
       2022) there is a "Report from the 2022 American Academy of
       Neurology Annual Meeting" that includes this as one of several
       highlighted presentations:
       [quote][font=ff-scala-sans-pro]COVID-19 RATES HIGH AMONG
       VACCINATED MS PATIENTS ON CERTAIN DISEASE-MODIFYING
       THERAPIES[/font]
       [font=ff-scala-sans-pro]Patients with multiple sclerosis (MS)
       who are fully vaccinated against COVID-19 and taking the
       disease-modifying drug ocrelizumab have higher rates of
       SARS-CoV-2 infection and hospitalization than those receiving
       other disease-modifying therapies, according to a new study.
       Patients taking fingolimod also had a higher rate of
       infection.[/font]
       [font=ff-scala-sans-pro]Using U.K. health databases, researchers
       assessed the incidence of SARS-CoV-2 infection and
       COVID-19-related hospitalization among roughly 38,000 patients
       with multiple sclerosis who were receiving disease-modifying
       therapies and had received two doses of COVID-19 vaccine.[/font]
       [font=ff-scala-sans-pro]From December 2020 to January 2022, the
       incidence of SARS-CoV-2 infection was 24% for patients who were
       taking ocrelizumab, 22% for fingolimod, and 11% to 16% for other
       disease-modifying therapies. Among those infected, the
       hospitalization rate was highest for ocrelizumab, at 7%,
       followed by 4% for fingolimod and 1% to 4% for other
       disease-modifying therapies.[/font]
       [font=ff-scala-sans-pro]Our clinician-guide, Dr. Seemant
       Chaturvedi, said: "This study provides thought-provoking data on
       the potential efficacy of COVID-19 vaccinations for certain MS
       patients on disease-modifying therapies."[/font][/quote]
       #Post#: 3734--------------------------------------------------
       (Abst.) Severity of COVID-19 among patients w/MS treated w/IFN-&
       #946;
       By: agate Date: August 4, 2022, 3:26 pm
       ---------------------------------------------------------
       From PubMed (August 4, 2022)--"Severity of COVID-19 infection
       among patients with multiple sclerosis treated with
       interferon-β":
  HTML https://pubmed.ncbi.nlm.nih.gov/35917745/
       *****************************************************